Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
1,485
Total raised
£42.6B
disclosed amounts
This month
£55.3M
raised so far
The home intelligence brand secured the investment after winning The Start Up Series competition.
"We have so many connected devices in the home from nanny cams and speakers to smart fridges, digital doorbells and games consoles, that we need security for all of them. Our vision is to protect at least two million homes and families from cyber-attacks by 2025 so this investment will support our efforts to grow substantially over the next 12 months in order to do so."
The publisher-focused data platform has secured £14m from Octopus Ventures and EQT Ventures to drive North American expansion and research.
"We’re really excited to announce this new milestone, which will help us to continue the momentum of helping publishers to understand and monetize their audiences. It’s our mission to reset advertising and to protect privacy while making data useful, and this funding will help us towards working for this goal."
The seed round was led by Nauta Capital to support platform enhancement and team growth.
"The idea of NumberEight started by asking a simple question: why can’t my sophisticated smartphone automatically recommend music to me based on my current mood and activity?"
The artificial intelligence data analytics business has secured an undisclosed amount of post-angel equity to expand its team and develop new products.
"Galytix has been strongly supported by its early investors who have brought their considerable experience to develop the company. We are delighted to welcome our new board members and investors who will help to propel the company to the next stage of growth. We thank our advisors PwC and Temple Bright."
The oversubscribed round was led by Cambridge Enterprise and will fund the company's transition into drug development.
"We are pleased to welcome on board our new investors and appreciate their confidence in our business. Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets, and are excited to now be able to invest in our own pipeline of drug discovery programmes, as well as to develop further strategic partnerships."
